Gilead Sciences Inc. (GILD) Stock Research, Analysis & News

Quick Analysis on Gilead Sciences Inc. (GILD) Stock as of December 16, 2018

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Gilead Sciences Inc. (GILD) Stock below)

Gilead Sciences Inc. (GILD) Stock Profile Summary

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The companys products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. The companys Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. Its Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. The company was founded in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc. (GILD) Stock Key Statistics Research and Analysis as of December 16, 2018

Gilead Sciences Inc. (GILD) Stock Competitor Research and Analysis

Bristol-Myers Squibb Company (BMY)GlaxoSmithKline plc (GSK)
Amgen Inc. (AMGN)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
Sanofi-Aventis (SNY)Novartis AG (NVS)

Mutual Funds with Gilead Sciences Inc. (GILD) Stock in its top 10 holdings

FundCategoryGILD Holding Percentage
Alger Large Cap Growth I-2Large Growth1.96%
American Century Disciplined Growth CLarge Growth2.11%
Invesco Global Growth CWorld Stock1.74%

ETFs with Gilead Sciences Inc. (GILD) Stock in its top 10 holdings

Stock Research on Gilead Sciences Inc. (GILD)

Latest Market News on Gilead Sciences Inc. (GILD)


Click here to find the latest news on Gilead Sciences Inc. (GILD)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Bristol-Myers Squibb Company (BMY)
GlaxoSmithKline plc (GSK)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
Sanofi-Aventis (SNY)
Novartis AG (NVS)